Compare HubSpot Inc (HUBS) vs Neurocrine Biosciences Inc (NBIX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
HubSpot Inc vs Neurocrine Biosciences Inc — how do they compare? HubSpot Inc trades at $224.17 (market cap $11.84B), while Neurocrine Biosciences Inc trades at $178.08 (market cap $17.40B). The key difference: Neurocrine Biosciences Inc is the larger of the two by market cap, and Neurocrine Biosciences Inc is trading nearer its 52-week high, HubSpot Inc nearer its low. Which is the better fit depends on your goals.
| HUBS | NBIX | |
|---|---|---|
Market Cap | $11.84B | $17.40B |
Sector | Technology | Health |
52-Week High | $560.90 | $180.55 |
52-Week Low | $170.39 | $123.10 |
Enterprise Value | $10.39B | $16.49B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
HubSpot (HUBS) trades at $231.36, up 3.17% with strong technical momentum and bullish moving averages. The company demonstrates robust revenue growth, reaching $3.13B in 2025 with expanding profit margins. Recent earnings consistently beat expectations, and analyst sentiment remains overwhelmingly positive with 81% buy ratings. Technical indicators show the stock approaching resistance at $232 with RSI levels suggesting potential overbought conditions.
HUBS presents compelling growth prospects with accelerating AI integration and customer expansion, though elevated valuation metrics and competitive pressures warrant caution. The stock's 14% upside to consensus target of $264.06 reflects optimism about continued execution, but investors should monitor margin sustainability and market volatility risks in the software sector.
Neurocrine Biosciences (NBIX) trades at $173.00, up 1.24% with strong bullish momentum. Recent earnings beats, including Q1 2026 EPS of $1.94 versus $1.22 expected, underscore robust growth. The stock shows bullish technical signals with support at $170 and resistance at $173. Revenue growth accelerated to $2.86 billion in 2025, with net income margin improving to 21.55% in 2026 projections. Positive news highlights pipeline advancements and the Soleno acquisition.
Outlook remains positive with a consensus price target of $196.08, implying 13% upside. Key opportunities include sustained earnings growth and pipeline expansion, while risks involve clinical trial outcomes and competitive pressures. Institutional sentiment is strongly bullish with 86% buy ratings.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About HubSpot Inc
HubSpot provides a cloud-based marketing, sales, and customer service software platform referred to as the growth platform. The applications are available ala carte or packaged together. HubSpot's mission is to help companies grow better and has expanded from its initial focus on inbound marketing to embrace marketing, sales, and service more broadly. The company was founded in 2006, completed its initial public offering in 2014, and is headquartered in Cambridge, Massachusetts.
Read more on HUBS →About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →
